In this special edition of Kidney Compass, Shikha Wadhwani sits down with Chee Kay Cheung, MBChB, PhD, of the University of Leicester, on the floor at the 62nd European Renal Association (ERA 2025) Congress to reflect on how far IgA nephropathy (IgAN) treatment has come—from what used to feel like “tumbleweeds” in nephrology to a pipeline packed with promising therapies.
At the top of the conversation: the rise of B-cell modulating therapies targeting APRIL and BAFF. Cheung highlights the interim results from the global phase 3 VISIONARY trial of sibeprenlimab, an APRIL inhibitor that achieved a 51.2% placebo-adjusted reduction in proteinuria at 9 months—the largest seen in any IgAN phase 3 study to date. Safety data were encouraging, with low discontinuation rates and a favorable overall profile.
Also on the radar: new long-term data from zigakibart, another anti-APRIL antibody, and promising topline results from atacicept, which targets both APRIL and BAFF. While head-to-head compa
All content for Kidney Compass: Navigating Clinical Trials is the property of Kidney Compass: Navigating Clinical Trials and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this special edition of Kidney Compass, Shikha Wadhwani sits down with Chee Kay Cheung, MBChB, PhD, of the University of Leicester, on the floor at the 62nd European Renal Association (ERA 2025) Congress to reflect on how far IgA nephropathy (IgAN) treatment has come—from what used to feel like “tumbleweeds” in nephrology to a pipeline packed with promising therapies.
At the top of the conversation: the rise of B-cell modulating therapies targeting APRIL and BAFF. Cheung highlights the interim results from the global phase 3 VISIONARY trial of sibeprenlimab, an APRIL inhibitor that achieved a 51.2% placebo-adjusted reduction in proteinuria at 9 months—the largest seen in any IgAN phase 3 study to date. Safety data were encouraging, with low discontinuation rates and a favorable overall profile.
Also on the radar: new long-term data from zigakibart, another anti-APRIL antibody, and promising topline results from atacicept, which targets both APRIL and BAFF. While head-to-head compa
Obinutuzumab, REGENCY, & Updates in Lupus Nephritis, With Brad Rovin, MD
Kidney Compass: Navigating Clinical Trials
31 minutes
1 week ago
Obinutuzumab, REGENCY, & Updates in Lupus Nephritis, With Brad Rovin, MD
Kidney Compass: Navigating Clinical Trials
In this special edition of Kidney Compass, Shikha Wadhwani sits down with Chee Kay Cheung, MBChB, PhD, of the University of Leicester, on the floor at the 62nd European Renal Association (ERA 2025) Congress to reflect on how far IgA nephropathy (IgAN) treatment has come—from what used to feel like “tumbleweeds” in nephrology to a pipeline packed with promising therapies.
At the top of the conversation: the rise of B-cell modulating therapies targeting APRIL and BAFF. Cheung highlights the interim results from the global phase 3 VISIONARY trial of sibeprenlimab, an APRIL inhibitor that achieved a 51.2% placebo-adjusted reduction in proteinuria at 9 months—the largest seen in any IgAN phase 3 study to date. Safety data were encouraging, with low discontinuation rates and a favorable overall profile.
Also on the radar: new long-term data from zigakibart, another anti-APRIL antibody, and promising topline results from atacicept, which targets both APRIL and BAFF. While head-to-head compa
